Home » Stocks » Heat Biologics

Heat Biologics, Inc. (HTBX)

Stock Price: $1.67 USD -0.16 (-8.74%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 248.10M
Revenue (ttm) 3.50M
Net Income (ttm) -20.28M
Shares Out 148.56M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $1.67
Previous Close $1.83
Change ($) -0.16
Change (%) -8.74%
Day's Open 1.72
Day's Range 1.63 - 1.73
Day's Volume 12,587,140
52-Week Range 0.20 - 4.30

More Stats

Market Cap 248.10M
Enterprise Value 202.95M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 148.56M
Float 143.74M
EPS (basic) -0.44
EPS (diluted) -0.38
FCF / Share -0.17
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.58M
Short Ratio 0.20
Short % of Float 9.54%
Beta 0.82
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 70.87
PB Ratio 10.47
Revenue 3.50M
Operating Income -18.52M
Net Income -20.28M
Free Cash Flow -14.99M
Net Cash 45.15M
Net Cash / Share 0.30
Gross Margin -284.65%
Operating Margin -529.11%
Profit Margin -579.30%
FCF Margin -428.34%
ROA -25.30%
ROE -59.43%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(162.28% upside)
Current: $1.67
Target: 4.38
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-47.37%281.19%344.89%-----
Gross Profit3.055.791.520.34----
Operating Income-20.13-17.46-13.12-13.13-21.02-12.19-6.56-2.35
Net Income-20.02-15.73-11.84-12.57-20.30-11.79-6.41-2.42
Shares Outstanding33.2817.493.851.760.800.650.370.18
Earnings Per Share-0.60-0.90-3.08-7.15-25.30-18.30-24.20-13.20
Operating Cash Flow-12.84-21.71-6.40-13.52-17.45-9.83-6.39-2.07
Capital Expenditures-0.16-0.59-0.06-0.05-0.12-0.46-0.05-
Free Cash Flow-12.99-22.31-6.46-13.57-17.56-10.29-6.44-2.08
Cash & Equivalents15.1528.089.848.0111.8014.5321.870.04
Total Debt1.93---6.752.71-0.92
Net Cash / Debt13.2228.089.848.015.0511.8221.87-0.88
Book Value13.5730.297.378.804.0511.7621.99-1.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Heat Biologics, Inc.
Country United States
Employees 36
CEO Jeff A. Wolf

Stock Information

Ticker Symbol HTBX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HTBX
IPO Date July 24, 2013


Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.